Cost-Effectiveness Analysis of Alemtuzumab In Comparison With Natalizumab, Intramuscular Interferon Beta-1a, Subcutaneous Interferon Beta-1b, And Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis In Iran

In the era of representing new medicines for the treatment of Multiple sclerosis, a highly debilitating immune mediated disorder, evaluating the incremental cost-effectiveness of medicines are necessary for allocating health care resources in an efficient manner. Therefore, this study was aimed to to assess the cost-effectiveness of Alemtuzumab (ALM) in comparison with Natalizumab (NTZ), intramuscular interferon beta-1a (IM-IFN), subcutaneous interferon beta-1b (SC-IFN), and fingolimod (FNG) for the treatment of relapsing-remitting multiple sclerosis (RRMS) from Iranian healthcare perspective.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research